Sugemalimab plus chemotherapy for relapsed NK/T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial studies whether sugemalimab (or a placebo) added to a chemotherapy plan can better control extranodal NK/T-cell lymphoma that has come back or didn’t respond to previous treatment. It may help patients by improving the chance of shrinking the tumor and extending how long the disease stays under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extranodal NK/T-cell lymphoma (ENKTL) confirmed by a pathology test from the study center.
- Your ENKTL has come back or is not responding after prior chemotherapy or chemoradiotherapy that included asparaginase.
- Your overall condition is good enough for treatment (ECOG performance status 0 to 2).
- You have at least one tumor area that can be measured on scans.
- You can share tumor tissue samples (stained slides and reports, or unstained tissue/block) for an expert central pathology review.
- Your major organs are working well enough for treatment, and you expect to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
This trial tests a combination of three medicines (sintilimab, chidamide, and azacitidine) to treat a rare blood cancer called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination can control the cancer better than traditional approaches.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.